About us

At Cambridge Cognition, we aim to improve the health of people around the world by discovering and delivering more effective brain health assessments and methods of administering them at home and in-clinic.

We develop digital technology solutions for cognitive assessments, electronic questionnaires and scales, and decentralised clinical trial solutions. Extraordinary accuracy, scientific discovery and validation are at the core of our business. This means that clinical scientists and academic researchers can trust our products and services to help them to deliver on their study goals and objectives.

Our digital assessments are targeted to specific cognitive domains, with increased data points and reduced noise compared to traditional assessments, making them more sensitive to subtle changes in cognition. For drug development we can help distinguish small effects by different drugs.

Our technology accurately assesses cognition anytime anywhere through mobile, tablet, browser and wearables, using touch and voice functionality.

Our story

1984

The Cambridge Neuropsychological Test Automated Battery (CANTAB®) is developed by Professor Barbara Sahakian and Professor Trevor Robbins at the University of Cambridge.

2002
Cambridge Cognition Ltd was spun out of the University of Cambridge to commercialise the CANTAB technology.
2012

CANTAB Mobile is launched, a tablet-based cognitive assessment tool for healthcare.

2013

Cambridge Cognition Ltd goes public on the AIM market of the London Stock Exchange. 

2015

Winterlight Labs is founded in Toronto, Canada by Frank Rudzicz, Katie Fraser, Liam Kaufman and Maria Yancheva.

2019

Launch of Cognition Kitâ„¢ for high-frequency testing on wearable devices such as smartwatches and fitness trackers.

2022

Virtual clinical trial solutions extended including remote patient monitoring, electronic informed consent and online data capture through the acquisition of eClinical Health.

2023

Cambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trials.

Who we work with

Supporting academic research through neuropsychological testing technologies, our solutions enable the discovery and enhanced understanding of factors in our biology and environment that affect cognitive function. We have facilitated the advancement of research across the world at top-ranking universities.

We offer a comprehensive solution for assessing cognitive safety and efficacy of drugs in development, from assessment technologies to study delivery. GCP compliant and suitable for use throughout all phases of clinical development, we combine leading scientific software with expert support, trusted by global pharmaceutical companies.

Our suite of healthcare technology solutions are designed to detect the earliest signs of clinically relevant memory problems, measure cognitive performance and assess wellbeing, in primary care and workplace settings, bringing cognitive assessments to patients and employees where they are.

Cambridge Cognition in numbers

0 +

indications assessed using our technologies

1 m+

patients assessed on our digital health tools

0 +

peer reviewed papers & articles

0 %

patient engagement

0 +

Countries

0 %

of our customers would recommend us

Meet some of our leaders

Alex Livingstone-Learmonth

Alex Livingstone-Learmonth

Joint Managing Director

Rob[58] copy

Rob Baker

Joint Managing Director

Francesca Cormack

Francesca Cormack

Chief Scientist

Ricky Dolphin

Ricky Dolphin

Chief Technology Officer

Maria Yancheva

Maria Yancheva

CTO Winterlight

Nick_Taptiklis_circle

Nick Taptiklis

Head of R&D Technology

Liam Kaufman

Liam Kaufman

VP Corporate Business Development

Annabelle Miles

Annabelle Miles

Head of Marketing

Careers

We are always looking for the best talent to join our growing team. Learn what it is like to work at Cambridge Cognition and find your next role.

Charity of the Year

Every year we select a charity to support, raising money through social activities, physical challenges, and volunteering opportunities. We are especially passionate about supporting charities that promote mental wellbeing and who provide support for people affected by neurological disorders – both the patients themselves and their families.
Scroll to Top